Panacos finds oral fusion inhibitors, provides development update on bevirimat

Panacos, a biotechnology company pioneering new classes of HIV drugs, says that it has found the first fusion inhibitors that could be administered orally, and is already working to develop second and third generation maturation inhibitors to bring to market alongside its lead maturation inhibitor, bevirimat.

Read More >>